Wendy Mayes, NP
Family · Clinton, TNNPI 1871930206
Payments from drug & device makers
Across 297 payments — averaging $32.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Pfizer$693
- Amgen$519
- Novo Nordisk$510
- Lilly USA, LLC$183
- Dexcom, Inc.$173
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$4,77050%
- Travel & lodging$841%
- Food & beverage$4,64849%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $5,559 |
| Pfizer | 41 | $693 |
| Amgen | 50 | $519 |
| Novo Nordisk | 29 | $510 |
| Lilly USA, LLC | 13 | $183 |
| Dexcom, Inc. | 8 | $173 |
| Boehringer Ingelheim | 10 | $161 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $160 |
| GSK | 9 | $160 |
| Astellas Pharma US Inc | 4 | $105 |
| Abbott | 5 | $94 |
| Merck | 5 | $90 |
| Phathom Pharmaceuticals, Inc. | 6 | $86 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $79 |
| Bayer | 4 | $72 |
| Inspire Medical Systems, Inc. | 1 | $71 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Idorsia Pharmaceuticals US Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Amarin Pharma, Inc. | 3 | $52 |
| Arbor Pharmaceuticals, Inc. | 3 | $49 |
| AstraZeneca | 3 | $49 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Philips North America LLC | 2 | $39 |
| Exact Sciences | 2 | $37 |
| Inogen, Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Silk Road Medical, Inc. | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Medtronic | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$4,770
How this compares
$9,563 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $79,843 |
| EliquisApixaban | 40 | $35,085 |
| MounjaroTirzepatide | 26 | $32,460 |
| JardianceEmpagliflozin | 14 | $23,457 |
| VraylarCariprazine Hcl | 12 | $14,435 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $13,297 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $8,214 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,058 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $2,006 |
| Fluticasone Propionate | 93 | $775 |
| Levothyroxine Sodium | 125 | $569 |
| Atorvastatin Calcium | 114 | $553 |
| Omeprazole | 63 | $515 |
| Losartan Potassium | 68 | $499 |
| Potassium Chloride | 53 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $510 | $79,84354 claims |
| PfizerEliquis | $693 | $35,08540 claims |
| Lilly USA, LLCMounjaro | $183 | $32,46026 claims |
| Boehringer IngelheimJardiance | $161 | $23,45714 claims |
| AbbVieVraylar | $5,559 | $14,43512 claims |
| AstraZenecaBreztri Aerosphere | $49 | $13,29720 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $31 | $4,05811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Clinton
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.